Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120222 · ClinicalTrials.gov registry record · Phase 1
Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
A Phase 1 study, sponsored by Kari Kendra.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02120222 is a Phase 1 study that has completed, run by Kari Kendra. The registered enrollment target is 8 participants.
The verdict
NCT02120222, a Phase 1 study, has completed, sponsored by Kari Kendra.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing.
Interventions
- OTHER Correlative studies
- DRUG selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-08-22 |
| Est. Completion | 2018-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02120222
The ClinicalTrials.gov registry entry for NCT02120222 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kari Kendra, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Correlative studies is the first listed.
NCT02120222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02120222 about?
NCT02120222 is a clinical study titled "Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery". This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing.
What is the current status of trial NCT02120222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2014-08-22. Estimated completion is 2018-04-08.
What interventions are being tested in trial NCT02120222?
The interventions under investigation include: Correlative studies (OTHER), selinexor (DRUG).
Who is sponsoring clinical trial NCT02120222?
This trial is sponsored by Kari Kendra, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.